Embecta

Embecta Capital Expenditures

The Capital Expenditures (CapEx) of Embecta (EMBC) as of Nov 21, 2026 is -9.30 M USD. In the previous year, Capital Expenditures (CapEx) was -15.80 M USD — a change of -41.14% (higher).

Capital Expenditures

-9.30 MUSD

YoY

-41.14%

Last updated:

Capital Expenditures (CapEx) of Embecta is 2025 -9.30 M USD. Capital Expenditures (CapEx) of Embecta was 2024 -15.80 M USD. It decreases by -41.14% higher compared to the previous year.

The Embecta Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-69.00 M USD
Jan 1, 2020
-41.90 M USD
Jan 1, 2021
-39.00 M USD
Jan 1, 2022
-24.00 M USD
Jan 1, 2023
-26.50 M USD
Jan 1, 2024
-15.80 M USD
Jan 1, 2025
-9.30 M USD
The Embecta Capital Expenditures history
YEARCapital ExpendituresYoY
-9.30 MUSD-41.14%
-15.80 MUSD-40.38%
-26.50 MUSD+10.42%
-24.00 MUSD-38.46%
-39.00 MUSD-6.92%
-41.90 MUSD-39.28%
-69.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Capital Expenditures (CapEx) of Embecta is -9.30 M USD in 2025.

Capital Expenditures (CapEx) of Embecta changed from -15.80 M USD to -9.30 M USD, representing a -41.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Embecta since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Embecta

All Key Metrics — Embecta